Medical News
inicio
sindicaci;ón

Archive for Crohn's

Cytokine Announces Oral Efficacy Of Anti Cytokine Semapimod

Cytokine PharmaSciences, Inc. (CPSI) announced development of an orally active form of semapimod, its synthetic anti cytokine compound. Semapimod is a potential treatment for inflammatory and autoimmune diseases including rheumatoid arthritis, Crohn’s and psoriasis. The compound has previously been tested in clinical trials only as an intravenous infusion and the newly developed oral form should significantly enhance its acceptability to patients and physicians.

Read the rest of this entry »

Elan And Biogen Idec Announce That Fda Will Extend Regulatory Review Period For Tysabri® For Crohn’s Disease

Joint FDA Advisory Committee Recommends Approval Of TYSABRI® For The Treatment Of Moderate To Severe Crohn’s Disease

Elan And Biogen Idec Preparing To Appeal Ruling On European Application For Natalizumab For The Treatment Of Crohn’s Disease

ECP May Be Effective In Treating Crohn’s Disease

In Crohn’s Disease CEACAM6 Helps E. Coli Stick To Intestinal Lining

Humira® Induced Clinical Remission In Patients With Crohn’s Disease Who Lost Response To, Or Were Intolerant To, Remicade®

CIMZIATM (Certolizumab Pegol) Maintained Response And Remission In Crohn’s Patients Previously Treated With Infliximab

Crohn’s & Colitis Foundation Of America And ConvaTec Announce 2006 Great Comebacks Regional Awards Recipients

Crohn’s & Colitis Foundation Of America And ConvaTec Announce 2006 Great Comebacks Regional Awards Recipients

« Previous entries · Next entries »